GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PharmaSGP Holding SE (XTER:PSG) » Definitions » Capex-to-Operating-Income

PharmaSGP Holding SE (XTER:PSG) Capex-to-Operating-Income : 0.10 (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is PharmaSGP Holding SE Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

PharmaSGP Holding SE's Capital Expenditure for the three months ended in Mar. 2025 was €-0.71 Mil. Its Operating Income for the three months ended in Mar. 2025 was €6.84 Mil.

Hence, PharmaSGP Holding SE's Capex-to-Operating-Income for the three months ended in Mar. 2025 was 0.10.


PharmaSGP Holding SE Capex-to-Operating-Income Historical Data

The historical data trend for PharmaSGP Holding SE's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaSGP Holding SE Capex-to-Operating-Income Chart

PharmaSGP Holding SE Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Income
Get a 7-Day Free Trial 0.06 5.59 0.05 0.04 0.05

PharmaSGP Holding SE Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.04 0.06 0.02 0.10

Competitive Comparison of PharmaSGP Holding SE's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, PharmaSGP Holding SE's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaSGP Holding SE's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PharmaSGP Holding SE's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where PharmaSGP Holding SE's Capex-to-Operating-Income falls into.


;
;

PharmaSGP Holding SE Capex-to-Operating-Income Calculation

PharmaSGP Holding SE's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-1.472) / 27.64
=0.05

PharmaSGP Holding SE's Capex-to-Operating-Income for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.708) / 6.836
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PharmaSGP Holding SE  (XTER:PSG) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


PharmaSGP Holding SE Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of PharmaSGP Holding SE's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmaSGP Holding SE Business Description

Traded in Other Exchanges
Address
Lochhamer Schlag 1, Graefelfing, Munich, DEU, 82166
PharmaSGP Holding SE is a pharmaceutical company. The company develops chemical-free, over-the-counter (OTC) drugs and healthcare products. The product portfolio includes RUBAXX for rheumatic pain Restaxil for nerve pain, and Deseo for sexual dysfunction. It has established various consumer brands in important indication areas, such as rheumatic and neuralgic pain or sexual weakness Also, the company offers products for skin aging and vertigo.
Executives
Dr. Clemens Fischer Supervisory Board
Madlena Hohlefelder Supervisory Board

PharmaSGP Holding SE Headlines

No Headlines